A Phase 2 interventional study of Baricitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company. Completed at 84 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-21.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 7th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 5th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 778 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
Drug: Baricitinib
Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
Drug: Baricitinib
Participants received Placebo orally once daily (QD) for 24 weeks.
Drug: Placebo
Administered orally
Also known as: LY3009104
Administered orally
Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Participants were defined as responder as follows using SLEDAI-2K definitions of arthritis and rash. If only arthritis is present at baseline, then arthritis must be absent at Week 24 to meet the primary endpoint. If only rash is present at baseline, then rash must be absent at Week 24 to meet the primary endpoint. If both arthritis and rash are present at baseline, then the primary endpoint is met if either arthritis, or rash, or both arthritis and rash are absent at Week 24.
Time frame: Week 24
Percentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response
SRI-4 response is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores; and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in Physician's Global Assessment of Disease Activity. The SRI-4 is a composite index used to assess disease activity in SLE. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe).
Time frame: Week 24
Change From Baseline in SLEDAI-2K Score
SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).
Time frame: Baseline, Week 24
Change From Baseline in Patient's Global Assessment of Disease Activity
The Patient's Global Assessment of Disease Activity is a single-item, patient reported scale developed for the assessment of the patient's overall rating of their disease activity due to SLE. The scale measures disease activity through a 5 point Likert scale ranging from 0 ("No disease activity") to 4 ("Severe disease activity") at its worst over the past 7 days. LS mean was determined by MMRM model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).
Time frame: Baseline, Week 24
Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss)
Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. AUC takes all time points post dose into account and one value is reported.
Time frame: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose
Population Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss)
Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. Cmax takes all time points post dose into account and one value is reported.
Time frame: Week (Wk) 0: 15-30 minutes (min) postdose; Wk 4: Predose, 1.5 - 4 hour (hr) postdose; Wk 8: 1 - 3 hr postdose; Wk 16: Predose
| Milestone | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Started | 105 | 105 | 104 |
| Received at least 1 dose of study drug | 105 | 105 | 104 |
| Completed | 83 | 86 | 86 |
| Not completed | 22 | 19 | 18 |
| Withdrew: Adverse event | 4 | 10 | 11 |
| Withdrew: Lack of efficacy | 9 | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Physician decision | 2 | 3 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 3 | 4 |
Participants were defined as responder as follows using SLEDAI-2K definitions of arthritis and rash. If only arthritis is present at baseline, then arthritis must be absent at Week 24 to meet the primary endpoint. If only rash is present at baseline, then rash must be absent at Week 24 to meet the primary endpoint. If both arthritis and rash are present at baseline, then the primary endpoint is met if either arthritis, or rash, or both arthritis and rash are absent at Week 24.
| Percentage of Participants | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) | 53.3 | 58.1 | 67.3 |
SRI-4 response is defined as: 1) Reduction of ≥4 points from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score; 2) no new British Isles Lupus Assessment Group (BILAG) A or no more than 1 new BILAG B disease activity scores; and 3) no worsening (defined as an increase of ≥0.3 points \[10 mm\] from baseline) in Physician's Global Assessment of Disease Activity. The SRI-4 is a composite index used to assess disease activity in SLE. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe).
| Percentage of Participants | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Percentage of Participants Who Achieve SLE Responder Index 4 (SRI-4) Response | 47.6 | 51.4 | 64.4 |
SLE Disease Activity Index 2000 (SLEDAI-2K) score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).
| Units on a scale | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Change From Baseline in SLEDAI-2K Score | -3.82 ± 0.352 | -4.07 ± 0.356 | -4.39 ± 0.353 |
The Patient's Global Assessment of Disease Activity is a single-item, patient reported scale developed for the assessment of the patient's overall rating of their disease activity due to SLE. The scale measures disease activity through a 5 point Likert scale ranging from 0 ("No disease activity") to 4 ("Severe disease activity") at its worst over the past 7 days. LS mean was determined by MMRM model with baseline of response, region, baseline disease activity (SLEDAI-2K \<10, \>=10), baseline anti-dsDNA status (positive, negative), treatment, time, treatment\*time (type III sum of squares).
| Units on a scale | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Change From Baseline in Patient's Global Assessment of Disease Activity | -0.67 ± 0.105 | -0.83 ± 0.107 | -1.00 ± 0.105 |
Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. AUC takes all time points post dose into account and one value is reported.
| nanogram*hour per milliliter (ng*h/mL) | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|
| Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUCτ, ss) | 265 ± 55 | 569 ± 50 |
Plasma samples for pharmacokinetic (PK) analysis were obtained in week 0, week 4, week 8, week 16 and 24. Cmax takes all time points post dose into account and one value is reported.
| nanogram per milliliter (ng/mL) | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|
| Population Pharmacokinetics (PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss) | 29.0 ± 30 | 59.2 ± 24 |
Collected over Up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/105 (0%) | 5/105 (4.8%) | 27/105 (25.7%) |
| 2 mg Baricitinib | 0/105 (0%) | 11/105 (10.5%) | 36/105 (34.3%) |
| 4 mg Baricitinib | 0/104 (0%) | 10/104 (9.6%) | 32/104 (30.8%) |
| Event | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/105 | 1/105 | 2/104 |
| DepressionPsychiatric disorders | 0/105 | 0/105 | 2/104 |
| AbortionPregnancy, puerperium and perinatal conditions | 0/99 | 1/96 | 0/99 |
| Cervical dysplasiaReproductive system and breast disorders | 0/99 | 1/96 | 0/99 |
| DiarrhoeaGastrointestinal disorders | 0/105 | 0/105 | 1/104 |
| Gastric ulcerGastrointestinal disorders | 0/105 | 0/105 | 1/104 |
| Intestinal perforationGastrointestinal disorders | 0/105 | 0/105 | 1/104 |
| NauseaGastrointestinal disorders | 0/105 | 0/105 | 1/104 |
| AppendicitisInfections and infestations | 0/105 | 0/105 | 1/104 |
| DiverticulitisInfections and infestations | 0/105 | 0/105 | 1/104 |
| Event | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 11/105 | 10/105 | 9/104 |
| Viral upper respiratory tract infectionInfections and infestations | 4/105 | 10/105 | 10/104 |
| Upper respiratory tract infectionInfections and infestations | 6/105 | 7/105 | 8/104 |
| PharyngitisInfections and infestations | 3/105 | 6/105 | 5/104 |
| HeadacheNervous system disorders | 3/105 | 6/105 | 3/104 |
| Age, Continuous(Years) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Total |
|---|---|---|---|---|
| Mean | 44.9 ± 12.8 | 43.2 ± 11.0 | 45.0 ± 12.4 | 44.3 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Total |
|---|---|---|---|---|
| Female | 99 | 96 | 99 | 294 |
| Male | 6 | 9 | 5 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 38 | 32 | 32 | 102 |
| Not Hispanic or Latino | 52 | 62 | 60 | 174 |
| Unknown or Not Reported | 15 | 11 | 12 | 38 |
| Race (NIH/OMB)(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 9 | 6 | 10 | 25 |
| Asian | 20 | 20 | 20 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 9 | 7 | 21 |
| White | 71 | 68 | 65 | 204 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | Total |
|---|---|---|---|---|
| Puerto Rico | 6 | 5 | 6 | 17 |
| Argentina | 9 | 12 | 7 | 28 |
| Austria | 3 | 2 | 3 | 8 |
| South Korea | 1 | 2 | 3 | 6 |
| Romania | 4 | 2 | 7 | 13 |
| United States | 31 | 34 | 30 | 95 |
| Japan | 13 | 10 | 10 | 33 |
| Taiwan | 6 | 7 | 5 | 18 |
| Poland | 13 | 10 | 9 | 32 |
| Mexico | 11 | 8 | 14 | 33 |
| France | 2 | 7 | 7 | 16 |
| Spain | 6 | 6 | 3 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Oct 2017, 18 months.
Results were first posted in Nov 2018, 1 year 1 month after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 18 months is below that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib
Lupus Erythematosus, Systemic →